⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 30, 2024VaccineOpen Access

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

Gebremedhin Beedemariam Gebretekle Man Wah Yeung Raphael Ximenes Alexandra Cernat Alison E. Simmons April Killikelly Winnie Siu Ellen Rafferty Nicholas Brousseau Matthew Tunis Ashleigh R. Tuite

View Full Paper

Ask AI

Bookmark

Share

Abstract

Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gebretekle et al. (2024) studied this question.

synapsesocial.com/papers/68e5e6e9b6db64358757b6ea https://doi.org/10.1016/j.vaccine.2024.126164

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants2024 · 3 citations
2Advances in preventing RSV in children2024 · 6 citations
3Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk InfantsOriginal Research · 2026 · 2 citations
4Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023Review · 2023 · 371 citations
5Choosing RSV Prevention: Maternal Vaccination or Nirsevimab?Cohort Study · 2026